Renal denervation
Renal denervation (RDN) is a catheter-based procedure that aims to lower blood pressure by interrupting the signals carried by the renal nerves, the nerves of the kidneys. The US device classification gives the purpose of the catheters as denervating the renal nerves to lower blood pressure. Two systems were approved for use in the United States in November 2023, one using ultrasound (P220023, 7 November 2023) and one using radiofrequency energy (P220026, 17 November 2023). Their original approval orders, the only ones read (later supplements were not), state an indication to reduce blood pressure as an adjunctive treatment in people with hypertension whose blood pressure lifestyle changes and medicines do not control well enough. A 2026 narrative review describes the evidence as showing a modest blood pressure effect; the page records the authors' view only and does not grade the trials.
Also called RDN · Renal sympathetic denervation
- Intervention
- In this atlas
Overview
Technical summary
No MeSH descriptor was found: a MeSH descriptor-label lookup for renal denervation on 2026-11-18 returned no match. Product code QYI (Ablation Catheter, Renal Denervation, class 3) of the US device classification is on the device page. Evidence in this atlas: the openFDA classification record for QYI, the openFDA records of the original approvals P220023 and P220026 (supplements not read) and PMC13607768 (Journal of Cardiovascular Development and Disease, 2026; CC BY 4.0), read for its abstract and one passage on the approved systems. No trial, registry entry or guideline was read for this page; the review's statements on guidelines, coverage and other topics are not carried over.
About this intervention
- Type
- Procedure
- Mechanism
- A catheter delivers energy from inside the renal arteries to interrupt renal sympathetic signalling; the two US-approved systems use ultrasound or radiofrequency energy, as a 2026 review describes.
Claims and evidence
Context People with uncontrolled and resistant hypertension, as a 2026 narrative review of catheter-based renal denervation describes them
- Recipient
- Recipient not specified
- Population
- People with uncontrolled or resistant hypertension, as the review's title and abstract describe them in general terms. The passages read give no age group and no trial population.
- Care setting
- Not applicable (narrative review, not a study)
- Geography
- Not stated for most passages; the approval sentence refers to the United States
- Life stage
- Not stated in the passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (narrative review)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
- Included
- None stated
- Excluded
- None stated
The authors of the same review state that, after a decade of controversy following the neutral SYMPLICITY HTN-3 trial, a coherent body of second-generation sham-controlled randomised evidence, generated with radiofrequency, endovascular ultrasound and perivascular alcohol platforms, has established a reproducible, modest and durable antihypertensive effect with a favourable safety profile. They list a direct comparison with newly approved pharmacotherapy and evidence of cardiovascular event reduction among questions that remain to be addressed.
Applies to Recipient not specified People with uncontrolled and resistant hypertension, as a 2026 narrative review of catheter-based renal denervation describes them
- Certainty method
- Not assessed
- Limitations
- These are the authors' own appraisal in a narrative review. No trial, effect size or safety figure was read for this page, and the review's own search ended in July 2026. The page records the authors' view and does not pool or grade the trials.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- Abstract, sentence 3, fragment 1 of 3
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
f987bc6e8ee0dc966b41adf91cfc7f0cae69a180b9162ef6e93fcb0a843716df- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own <license> element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Abstract, sentence 3, fragment 2 of 3
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
f987bc6e8ee0dc966b41adf91cfc7f0cae69a180b9162ef6e93fcb0a843716df- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own <license> element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Abstract, sentence 3, fragment 3 of 3
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
f987bc6e8ee0dc966b41adf91cfc7f0cae69a180b9162ef6e93fcb0a843716df- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own <license> element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Abstract, sentence 6, fragment
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
f987bc6e8ee0dc966b41adf91cfc7f0cae69a180b9162ef6e93fcb0a843716df- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own <license> element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
A 2026 narrative review says catheter-based renal denervation interrupts efferent and afferent renal sympathetic signalling. It says two systems hold US Food and Drug Administration approval: the Paradise endovascular ultrasound system (Recor Medical), approved on 7 November 2023, and the SYMPLICITY Spyral radiofrequency system (Medtronic), approved on 17 November 2023.
Applies to Recipient not specified People with uncontrolled and resistant hypertension, as a 2026 narrative review of catheter-based renal denervation describes them
- Certainty method
- Not assessed
- Limitations
- A narrative review by its authors, not a study. The approval dates agree with the openFDA records of P220023 and P220026 read for the device page. Other parts of the review, including its statements on guidelines and coverage, were not carried into this atlas.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- Abstract, sentence 2, fragment
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
f987bc6e8ee0dc966b41adf91cfc7f0cae69a180b9162ef6e93fcb0a843716df- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own <license> element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- 3. Device Platforms and Procedural Techniques, paragraph 1, sentence 1, fragment 1 of 2
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
f987bc6e8ee0dc966b41adf91cfc7f0cae69a180b9162ef6e93fcb0a843716df- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own <license> element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- 3. Device Platforms and Procedural Techniques, paragraph 1, sentence 1, fragment 2 of 2
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
f987bc6e8ee0dc966b41adf91cfc7f0cae69a180b9162ef6e93fcb0a843716df- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own <license> element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact A 2026 review describes two US-approved renal denervation systems: Hypertension (high blood pressure)
Applies to Recipient not specified People with uncontrolled and resistant hypertension, as a 2026 narrative review of catheter-based renal denervation describes them
A 2026 narrative review says catheter-based renal denervation interrupts efferent and afferent renal sympathetic signalling. It says two systems hold US Food and Drug Administration approval: the Paradise endovascular ultrasound system (Recor Medical), approved on 7 November 2023, and the SYMPLICITY Spyral radiofrequency system (Medtronic), approved on 17 November 2023.Limitations. A narrative review by its authors, not a study. The approval dates agree with the openFDA records of P220023 and P220026 read for the device page. Other parts of the review, including its statements on guidelines and coverage, were not carried into this atlas.
-
Claim, not a settled fact The same review gives the authors' appraisal of the sham-controlled evidence: Hypertension (high blood pressure)
Applies to Recipient not specified People with uncontrolled and resistant hypertension, as a 2026 narrative review of catheter-based renal denervation describes them
The authors of the same review state that, after a decade of controversy following the neutral SYMPLICITY HTN-3 trial, a coherent body of second-generation sham-controlled randomised evidence, generated with radiofrequency, endovascular ultrasound and perivascular alcohol platforms, has established a reproducible, modest and durable antihypertensive effect with a favourable safety profile. They list a direct comparison with newly approved pharmacotherapy and evidence of cardiovascular event reduction among questions that remain to be addressed.Limitations. These are the authors' own appraisal in a narrative review. No trial, effect size or safety figure was read for this page, and the review's own search ended in July 2026. The page records the authors' view and does not pool or grade the trials.
Record details
- Record id
cardio:renal-denervation- Content hash
9c470364d8b80cc7f257b5612a0dcaf1b03fbff15e6dcad5f5ae4c87a8048d50